Merck & Co., Inc. Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

15 equities research analysts have issued 12 month price targets for Merck & Co., Inc.'s shares. Their MRK stock forecasts range from $70.00 to $110.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $91.60 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Merck & Co., Inc.'s stock was trading at $76.64 at the beginning of the year. Since then, MRK shares have increased by 21.5% and is now trading at $93.13.
View the best growth stocks for 2022 here.

Merck & Co., Inc. saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 21,570,000 shares, an increase of 27.0% from the April 30th total of 16,980,000 shares. Based on an average daily trading volume, of 11,500,000 shares, the short-interest ratio is currently 1.9 days.
View Merck & Co., Inc.'s Short Interest.

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Thursday, April, 28th. The company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.81 by $0.33. The firm had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a trailing twelve-month return on equity of 47.86%. The business's revenue was up 31.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.40 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 24th. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.69 per share on Friday, July 8th. This represents a $2.76 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date of this dividend is Tuesday, June 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc.(NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.00%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 49.37%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.39% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $7.24-$7.36 for the period, compared to the consensus EPS estimate of $7.24. The company issued revenue guidance of $56.90 billion-$58.10 billion, compared to the consensus revenue estimate of $57.35 billion.

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of MRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.55%), BlackRock Inc. (8.07%), State Street Corp (4.68%), Wellington Management Group LLP (1.81%), Bank of New York Mellon Corp (1.30%) and Charles Schwab Investment Management Inc. (1.19%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Bank of Nova Scotia, Toronto Dominion Bank, First Trust Advisors LP, Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., and Bahl & Gaynor Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last two years include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

MRK stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Caisse DE Depot ET Placement DU Quebec, Bank of New York Mellon Corp, Arrowstreet Capital Limited Partnership, Swiss National Bank, and Capital Wealth Planning LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRK stock can currently be purchased for approximately $93.13.

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $235.51 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $5.59 on an earnings per share basis.

Merck & Co., Inc. employs 68,000 workers across the globe.

Merck & Co., Inc. was founded in 1891.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for Merck & Co., Inc. is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.